Acadia Pharmaceuticals price target raised to $25 from $22 at Guggenheim

Guggenheim analyst Yatin Suneja raised the firm’s price target on Acadia Pharmaceuticals to $25 from $22 and keeps a Buy rating on the shares after the FDA approved trofinetide, now Daybue, as "the first and only" Rett syndrome treatment and gave it "a broad label." With an average list price per year of $575,000-595,000 assumed, the company expects the average net realized cost of Daybue to be about $375,000, which was above the firm’s and Street estimates, the analyst tells investors.